2020
Pathophysiology and Treatment of Enteric Hyperoxaluria
Witting C, Langman C, Assimos D, Baum M, Kausz A, Milliner D, Tasian G, Worcester E, Allain M, West M, Knauf F, Lieske J. Pathophysiology and Treatment of Enteric Hyperoxaluria. Clinical Journal Of The American Society Of Nephrology 2020, 16: 487-495. PMID: 32900691, PMCID: PMC8011014, DOI: 10.2215/cjn.08000520.Peer-Reviewed Original ResearchConceptsEnteric hyperoxaluriaGastrointestinal disordersBariatric surgical proceduresCurrent therapeutic optionsAvailable treatment strategiesUrinary oxalate excretionKidney stone eventsLong-term efficacyKidney Health InitiativeNew therapeutic approachesComplicated obesityDietary modificationFat malabsorptionOxalate excretionTherapeutic optionsAdverse outcomesKidney failureStone eventsTreatment strategiesDietary oxalateSurgical proceduresTherapeutic approachesSevere casesHyperoxaluriaHealth initiatives
2017
Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo
Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology 2017, 34: 91. PMID: 28397106, PMCID: PMC5896014, DOI: 10.1007/s12032-017-0956-8.Peer-Reviewed Original ResearchConceptsEpithelial ovarian carcinomaOvarian carcinoma xenograftsOvarian cancerOvarian carcinomaCarcinoma xenograftsPreclinical efficacyCell linesTumor cell linesHER2/neu expressionChemotherapy-resistant diseaseOvarian cancer cell linesAvailable treatment strategiesEfficacy of neratinibInhibits xenograft growthNovel therapeutic agentsPrimary tumor cell linesG0/G1 phaseCell cycle distributionCell signaling changesNeratinib treatmentCancer cell linesGynecologic malignanciesOverall survivalNeu expressionClinical trials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply